血清miR-22可预测弥漫大B细胞淋巴瘤不良结局与治疗反应
本研究在弥漫大B细胞淋巴瘤(DLBCL)中验证血清miR-22作为预后/预测生物标志物,发现其表达及从DLBCL细胞的释放与治疗反应相关,并 adverse 影响细胞增殖,提示miR-22是有前景的互补或独立无创生物标志物。
要点
- 血清miR-22与DLBCL治疗反应相关。
- miR-22表达及释放影响DLBCL细胞增殖。
- miR-22可作为互补或独立无创预后标志物。
核心结论
- 血清miR-22是DLBCL有前景的互补或独立无创预后/预测生物标志物。
研究设计与样本
- 在DLBCL患者中验证血清miR-22作为预后/预测生物标志物的研究。
主要发现
- 血清miR-22表达及其从DLBCL细胞的释放与治疗反应相关。
- miR-22对DLBCL细胞增殖产生 adverse 影响。
临床怎么用
- 可考虑将血清miR-22作为DLBCL预后评估和治疗反应预测的补充无创标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diffuse large B-cell lymphoma (DLBCL) is an aggressive, heterogeneous neoplasm where prognostication and therapeutic decision are challenging. The available prognostic tools are not able to identify all patients refractory to treatment. MicroRNAs, small RNAs frequently deregulated in cancer, stably circulate in biofluids, representing interesting candidates for non-invasive biomarkers. Here we validated serum miR-22, an evolutionarily conserved microRNA, as a prognostic/predictive biomarker in DLBCL. Moreover, we found that its expression and release from DLBCL cells are related to therapy response and adversely affect cell proliferation. These results suggest that miR-22 is a promising complementary or even independent non-invasive biomarker for DLBCL management.
引用
- Rinaldi F, Marchesi F, Palombi F, et al. MiR-22, a serum predictor of poor outcome and therapy response in diffuse large B-cell lymphoma patients. Br J Haematol. 2021. PMID: 34318932. doi:10.1111/bjh.17734
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。